I. Background of International Standard Approval
On June 4, 2026, according to the Standardization Administration of China, two international standard proposals, 'Surgical Implants - Recombinant Collagen' and 'Surgical Implants - Silk Fibroin', led by Chinese experts, were officially approved for development. This is the first time globally that an international standard system is being established for recombinant collagen and silk fibroin in the field of surgical implants.
China serves as the project leader for both standards, with experts from the United States, Germany, France, and other countries participating in their development. This marks China's transition from an industry participant to an international rule-maker in the core biomaterial field of recombinant collagen.
II. Framework of Standard Content
According to public information, the two standards will establish a complete quality evaluation system for recombinant collagen and silk fibroin, including the following aspects:
- Physicochemical indicators
- Purity and impurity control
- Structural characterization
- Safety evaluation
- Stability testing
- Biological evaluation methods
Han Qianqian, Director of the Institute for Medical Device Control at the National Institutes for Food and Drug Control, stated that the two standards establish a systematic indicator system from production process control to final product quality control for the first time, filling the gap in international standards for bio-based materials in the surgical implant field.
III. Industry Data Reference
According to data released by Frost & Sullivan, the market size of recombinant collagen products in China exceeded 38 billion yuan in 2023 and is expected to surpass 200 billion yuan by 2030. The approval of these two international standards will provide standardized support for domestic high-quality medical materials to enter the international market.
In addition, in June 2026, the Chinese Society for Biomaterials approved the development of the group standard 'Recombinant Type III Human Collagen', jointly drafted by Guangzhou Chuang'er Biotechnology, South China University of Technology, the Institute of Process Engineering of the Chinese Academy of Sciences, Sichuan University, and other institutions. The standard development period is from June 2026 to June 2028.
In this rapidly developing track, Weitai Biotechnology, as a leading contract manufacturer in the recombinant collagen field, has independently developed recombinant humanized type III collagen (purity ≥95%) and has developed multiple medical dressings and functional skincare products based on this core raw material. From raw materials to finished products, we hold more than 110 Class II medical device registration filings, GMPC and ISO dual certification systems, and four factories operating in coordination, ensuring both capacity and quality.
IV. Impact on the Industry
In recent years, recombinant collagen has gradually expanded from the medical device field to dressings, injectable fillers, functional skincare, and other tracks. However, products from different companies vary in molecular structure, purity levels, and activity retention, and the industry lacks a set of internationally recognized evaluation standards. The establishment of these international standards will help:
- Unify the quality evaluation framework for recombinant collagen
- Reduce cross-border duplicate testing barriers
- Promote the internationalization of domestic raw materials
- Provide technical reference for downstream product development
Ultimately, the key is not just setting standards but implementing them. Weitai Biotechnology will continue to follow the development process of international standards, internalize the standard requirements into production processes, and provide OEM/ODM customers with contract manufacturing services for recombinant collagen products that comply with international standards—from formula development and registration application to large-scale production, with full-process support.
Weitai Biotechnology · Recombinant Collagen OEM/ODM Services
Currently, Weitai Biotechnology has served hundreds of brand clients, including well-known brands such as Baiyunshan, and has accumulated mature mass production experience in product lines such as recombinant collagen dressings, repair creams, and care liquids. Mature products such as our medical recombinant type III human collagen dressing (Xiang Medical Device Registration No. 20222140503), medical recombinant collagen repair cream (Xiang Medical Device Registration No. 20242140072), and medical recombinant collagen repair liquid (Qiong Medical Device Registration No. 20252140091) can directly serve as basic solutions for OEM cooperation.
Four Major Production Bases
- Guangzhou Weitai Factory: No. 77, She 15, Dalang Village, Baiyunhu Street, Baiyun District, Guangzhou
- Guangdong Weitai Factory: No. 18, Taoyuan East Road, Songxia Industrial Park, Songgang, Shishan Town, Nanhai District, Foshan
- Guangdong Jinan Gene Factory: Factory Building 23, Hongguang Industrial Park, No. 2 Wende Fifth Street, Zhaoqing High-tech Zone, Zhaoqing, Guangdong Province
- Hunan Weitai Factory: Room 501, Building 11, Lanyuegu Intelligent Industrial Park, Xieyuan North Road, Ningxiang Economic Development Zone, Changsha, Hunan Province
Brands with customized recombinant collagen product needs are welcome to contact us to obtain cooperation solutions.
Sources: Standardization Administration of China, Chinese Society for Biomaterials, Frost & Sullivan, CNR